BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38310085)

  • 21. Diagnostic accuracy of serum protein induced by vitamin K absence (PIVKA-II), serum a-fetoprotein and their combination for hepatocellular carcinoma among Caucasian cirrhotic patients with diagnostic or non-diagnostic serum a-fetoprotein levels.
    Syriha A; Pantzios S; Mandilara D; Galanis P; Stathopoulou I; Barla G; Elefsiniotis I
    Cancer Med; 2024 Feb; 13(3):e6825. PubMed ID: 38361401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
    Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
    Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
    Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
    Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma.
    Jang ES; Jeong SH; Kim JW; Choi YS; Leissner P; Brechot C
    PLoS One; 2016; 11(3):e0151069. PubMed ID: 26986465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study.
    Wang MD; Sun LY; Qian GJ; Li C; Gu LH; Yao LQ; Diao YK; Pawlik TM; Lau WY; Huang DS; Shen F; Yang T
    Int J Surg; 2022 Sep; 105():106843. PubMed ID: 35995351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma.
    Tian S; Chen Y; Zhang Y; Xu X
    J Clin Lab Anal; 2023 Jan; 37(1):e24823. PubMed ID: 36579611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
    Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
    Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients.
    Hadi H; Wan Shuaib WMA; Raja Ali RA; Othman H
    Medicina (Kaunas); 2022 Jul; 58(8):. PubMed ID: 36013482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The value of serum abnormal prothrombin in clinical application of hepatocellular carcinoma].
    Zhang JW; Guan LY; E CY; Yang JH; Xuan W; Meng ZH; Li W
    Zhonghua Wai Ke Za Zhi; 2020 Oct; 58(10):776-781. PubMed ID: 32993265
    [No Abstract]   [Full Text] [Related]  

  • 31. A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B.
    Yang T; Xing H; Wang G; Wang N; Liu M; Yan C; Li H; Wei L; Li S; Fan Z; Shi M; Chen W; Cai S; Pawlik TM; Soh A; Beshiri A; Lau WY; Wu M; Zheng Y; Shen F
    Clin Chem; 2019 Dec; 65(12):1543-1553. PubMed ID: 31672853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
    Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma.
    Malik J; Klammer M; Rolny V; Chan HL; Piratvisuth T; Tanwandee T; Thongsawat S; Sukeepaisarnjaroen W; Esteban JI; Bes M; Köhler B; Swiatek-de Lange M
    World J Gastroenterol; 2022 Aug; 28(29):3917-3933. PubMed ID: 36157551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
    Beale G; Chattopadhyay D; Gray J; Stewart S; Hudson M; Day C; Trerotoli P; Giannelli G; Manas D; Reeves H
    BMC Cancer; 2008 Jul; 8():200. PubMed ID: 18638391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents.
    Degasperi E; Perbellini R; D'Ambrosio R; Uceda Renteria SC; Ceriotti F; Perego A; Orsini C; Borghi M; Iavarone M; Bruccoleri M; Rimondi A; De Silvestri A; Sangiovanni A; Lampertico P
    Aliment Pharmacol Ther; 2022 Feb; 55(3):350-359. PubMed ID: 34738664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein.
    Suehiro T; Sugimachi K; Matsumata T; Itasaka H; Taketomi A; Maeda T
    Cancer; 1994 May; 73(10):2464-71. PubMed ID: 7513601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy.
    Loglio A; Iavarone M; Facchetti F; Di Paolo D; Perbellini R; Lunghi G; Ceriotti F; Galli C; Sandri MT; Viganò M; Sangiovanni A; Colombo M; Lampertico P
    Liver Int; 2020 Aug; 40(8):1987-1996. PubMed ID: 32301212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
    Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
    Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology.
    Caviglia GP; Ciruolo M; Abate ML; Carucci P; Rolle E; Rosso C; Olivero A; Troshina G; Risso A; Nicolosi A; Ribaldone DG; Armandi A; Tandoi F; Saracco GM; Bugianesi E; Ciancio A; Gaia S
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33142893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis.
    Xu C; Yan Z; Zhou L; Wang Y
    J Cancer Res Clin Oncol; 2013 Aug; 139(8):1417-24. PubMed ID: 23743582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.